Target Price | $5.20 |
Price | $2.17 |
Potential |
139.63%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Maravai LifeSciences 2026 .
The average Maravai LifeSciences target price is $5.20.
This is
139.63%
register free of charge
$10.00
360.83%
register free of charge
$2.00
7.83%
register free of charge
|
|
A rating was issued by 14 analysts: 7 Analysts recommend Maravai LifeSciences to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2026 of
139.63%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 259.19 | 194.85 |
10.30% | 24.82% | |
EBITDA Margin | -26.27% | -13.80% |
236.12% | 47.46% | |
Net Margin | -55.89% | -89.74% |
35.66% | 60.58% |
14 Analysts have issued a sales forecast Maravai LifeSciences 2025 . The average Maravai LifeSciences sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Maravai LifeSciences EBITDA forecast 2025. The average Maravai LifeSciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Maravai LifeSciences Analysts have issued a net profit forecast 2025. The average Maravai LifeSciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.05 | -0.69 |
16.67% | 34.29% | |
P/E | negative | |
EV/Sales | 3.05 |
3 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences EPS is
This results in the following potential growth metrics and future valuations:
Maravai LifeSciences...
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | May 13 2025 |
Craig-Hallum |
Locked
➜
Locked
|
Locked | May 13 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
UBS |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
May 13 2025 |
Locked
Craig-Hallum:
Locked
➜
Locked
|
May 13 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
UBS:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 05 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.